Q3 EPS Estimate for Eupraxia Pharmaceuticals Cut by Analyst

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for Eupraxia Pharmaceuticals to ($0.20), down from the previous estimate of ($0.18).
• The company's recent quarterly earnings report showed a loss of ($0.26) per share, missing analysts' consensus estimates of ($0.21) by ($0.05).
• Eupraxia Pharmaceuticals holds a Buy rating from HC Wainwright, with a price target set at $12.00, while the stock has a current market capitalization of $189.87 million.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2025 EPS estimates for Eupraxia Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.20) for the quarter, down from their previous estimate of ($0.18). HC Wainwright currently has a "Buy" rating and a $12.00 target price on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. HC Wainwright also issued estimates for Eupraxia Pharmaceuticals' Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.80) EPS, FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($1.01) EPS, FY2028 earnings at ($1.04) EPS and FY2029 earnings at ($0.26) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05).

EPRX has been the topic of several other research reports. Canaccord Genuity Group initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They issued a "speculative buy" rating on the stock. Cantor Fitzgerald initiated coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, July 24th. They issued an "overweight" rating and a $11.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $11.00.

Eupraxia Pharmaceuticals Trading Up 1.5%

NASDAQ:EPRX traded up $0.08 during mid-day trading on Friday, hitting $5.38. The stock had a trading volume of 10,344 shares, compared to its average volume of 13,360. The stock has a 50-day simple moving average of $5.10 and a two-hundred day simple moving average of $4.16. The company has a market capitalization of $193.46 million, a PE ratio of -6.33 and a beta of 1.50. Eupraxia Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $6.20.

Institutional Trading of Eupraxia Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EPRX. Millennium Management LLC acquired a new stake in Eupraxia Pharmaceuticals during the fourth quarter worth approximately $31,000. Raymond James Financial Inc. acquired a new position in shares of Eupraxia Pharmaceuticals in the 4th quarter valued at $37,000. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at $61,000. Bank of America Corp DE increased its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after acquiring an additional 10,059 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Eupraxia Pharmaceuticals by 593.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company's stock valued at $108,000 after acquiring an additional 16,017 shares during the period.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.